Spyre Therapeutics, Inc. SYRE Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableTrade.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s accounts payable?
- Spyre Therapeutics, Inc. (SYRE) reported accounts payable of -$3.21M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s accounts payable changed year-over-year?
- Spyre Therapeutics, Inc.'s accounts payable decreased by 206.3% year-over-year, from $3.02M to -$3.21M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s accounts payable?
- Over 2 years (2021 to 2025), Spyre Therapeutics, Inc.'s accounts payable has grown at a 178.1% compound annual growth rate (CAGR), from $1.07M to $8.24M.